- Home
- ACIC vs NGNE Comparison
ACIC vs NGNE Comparison
Compare ACIC & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACIC | NGNE |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 540.4M | 498.2M |
| IPO Year | 2007 | 2014 |
Fundamental Metrics
Financial Performance| Metric | ACIC | NGNE |
|---|---|---|
| Price | $10.15 | $39.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | N/A | ★ $63.57 |
| AVG Volume (30 Days) | 297.9K | ★ 305.2K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 6.33% | N/A |
| EPS Growth | ★ 39.61 | 0.93 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.00 | N/A |
| P/E Ratio | $27.72 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.80 | $15.93 |
| 52 Week High | $13.06 | $43.66 |
Technical Indicators
Market Signals| Indicator | ACIC | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 34.52 | 63.72 |
| Support Level | $9.80 | $18.24 |
| Resistance Level | $11.52 | N/A |
| Average True Range (ATR) | 0.35 | 3.11 |
| MACD | -0.08 | 0.51 |
| Stochastic Oscillator | 1.89 | 70.00 |
Price Performance
Historical ComparisonAbout ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.